Rahul Aggarwal (@RahulAggarwalMD) profile picture

Cardiology Fellow @HarvardMed @BrighamWomens | Clinical Trials, Health Innovation, AI | Thankful for Friends & Family

Harvard Medical School
Joined October 2018
Photo by Rahul Aggarwal (@RahulAggarwalMD)Photo by Rahul Aggarwal (@RahulAggarwalMD)Photo by Rahul Aggarwal (@RahulAggarwalMD)Photo by Rahul Aggarwal (@RahulAggarwalMD)Photo by Rahul Aggarwal (@RahulAggarwalMD)Photo by Rahul Aggarwal (@RahulAggarwalMD)Photo by Rahul Aggarwal (@RahulAggarwalMD)Photo by Rahul Aggarwal (@RahulAggarwalMD)
1/ Our NEW @CircAHA study, simultaneously published with #ESCCongress 🚨 We develop and validate the NEW #DOAC Score ➡️ A bleeding risk score for patients with #afib on DOACs ✅ We find our DOAC Score outperforms prior risk scores, including the HAS-BLED tinyurl.com/3fzr65jy – at Amsterdam, The Netherlands
6
65
18
209
77,520
Excited to share our @CircHF editorial on a REHAB-HF study answering: "Who benefits most from HF rehab?" @DrDamluji @robmentz found Pts. who were the most inflamed by hsCRP gained the most from rehab Thanks to @ambarish4786 @DrNancySweitzer for the opportunity to contribute!
3
10
1
37
2,454
2+ years ago, @vivnat and I asked a simple question with our amazing team @GoogleDeepMind @GoogleResearch: what would it take for conversational diagnostic AI to safely enter into a real medical clinic? That sparked many London<>Boston flights over the pond, enduring friendship and collaboration with @AdamRodmanMD @BIDMChealth and our amazing teammates, rigorous safe-stopping protocols, and our first prospective study now in @TheLancet: goo.gle/4i7Fx9N
10
14
113
6,916
Rahul Aggarwal retweeted
Our clinical trial of AMIE, a patient-facing AI system, was just published in The Lancet. I want to explain what *I* think this study ACTUALLY means. It's about a fundamental question: how do we know that clinical AI works? 🧵⬇️ teapaw.org/Google/status/21083245…
Our medical research system, AMIE, is the first patient-facing conversational diagnostic tool of its kind to be studied prospectively in a real-world clinical setting. In a study, published today in @TheLancet, we found that when patients chatted with AMIE before an in-person appointment, the interaction built their confidence and helped them organize their thoughts. And physicians who reviewed the information from the patient conversation got more time back to focus on collaborative care and shared decision-making instead of digging through data.
15
60
10
219
29,711
“How do we judge success after a HTN intervention?” Our @JACCJournals editorial on the China Rural HTN Project details what we learn from this study 🔑 lessons for scaling implementation in rural US Thanks @AmbarishPandey @hmkyale for the opportunity! doi.org/10.1016/j.jacc.2026.…
1
3
22
1,063
Our editorial in @JCFINT on HF STATS 2026: HF STATS highlights how uneven HF progress remains. @rkwadhera and I discuss how Medicaid expansion, the IRA, rural financing, and new care models—including AI-supported titration—could narrow these gaps. 🔗sciencedirect.com/science/ar…
3
5
15
675
Rahul Aggarwal retweeted
Excited for the launch of the Smith Institute for Evidence, Innovation, and Policy—tackling health care’s biggest questions and turning evidence into better care and healthier lives Honored to serve as Director of the Institute & lead this next chapter with @rwyeh @BIDMChealth Read more: bidmc.org/news-stories/all-n…
After a decade of growth, we’re now the Richard A. and Susan F. Smith Institute for Evidence, Innovation, and Policy. The Institute's centers will bring together bold ideas, rigorous science, and clinical expertise to improve people’s health and lives. bidmc.org/news-stories/all-n…
6
19
1
81
4,661
Excited to share our NEW paper @JACCJournals #JACCHF on inflammatory risk in HF In Look AHEAD, we find IL-6 identified risk of HF in T2D & obesity Lifestyle w/ weight loss ⬇️ IL-6 doi.org/10.1016/j.jchf.2026.… 🙏 to team @kershawpatel @JavedButler1 @CBallantyneMD @ambarish4786
5
10
47
3,524
Grateful to work w/ Peter Libby & team on our new @JAMACardio paper: how do we actually run CV outcomes trials in Clonal Hematopoiesis? Genetic heterogeneity, clone size, recruitment, competing risks, and statistical power all complicate trial design. 🔗jamanetwork.com/journals/jam…
1
6
1
33
2,777
Excited to share our @JACCJournals Viewpoint on CMS ACCESS & the future of CKM care 🫀 💡ACCESS is the 1st payment model aligned w/ the @American_Heart CKM framework & may reshape how care is reimbursed. Also this issue: CKM analysis by @Gong2Jingyi 🔗jacc.org/doi/10.1016/j.jacc.…
1
4
1
18
4,960
🚨 Our new publication in @JAHA_AHA: 🌾What are tradeoffs of Medicare Advantage in rural America? Using data from 16.4 million rural beneficiaries with CV conditions, we found: ✅ Better preventive care access 💸 More problems paying medical bills 📄 doi.org/10.1161/JAHA.125.050…
1
5
22
1,284
Proud to be part of this work in @JACCJournals led by @Gong2Jingyi examining treatment and control of cardiometabolic risk factors among U.S. adults with cardiovascular-kidney-metabolic (CKM) syndrome. Thank you to @rkwadhera for outstanding mentorship as always!
Our new @JACCJournals study shows that even in a higher-risk population - adults with CKM syndrome - roughly half are going untreated for major risk factors Even among those who are treated, control is elusive. Led by @Gong2Jingyi jacc.org/doi/10.1016/j.jacc.…
1
4
18
2,053
Rahul Aggarwal retweeted
There has ALREADY been a lot written about NYU @openevidence @UpToDate Expert AI study but wanted to give my perspective as what counts for an "expert" in human-computer interaction these days. Especially when I see Twitter debates about item response theory. 🤣 A 🧵⬇️
For medical information, general AI frontier models (Google, OpenAI, Anthropic) outperformed specialized @openevidence and @UpToDate as assessed by 12 US clinicians, randomized and blinded to which model and extensive testing/benchmarks. This was not anticipated. @NatureMedicine nature.com/articles/s41591-0…
11
30
4
142
59,198
Rahul Aggarwal retweeted
#ResearchLetter: Locally deployed LLMs accurately adjudicate heart failure hospitalizations at cardiologist-level accuracy, as an approach to reduce cardiovascular trial costs. ahajrnls.org/4vEq8mk
3
8
1
22
7,075
Can AI transform clinical trials? Published in @CircAHA, our team tested whether locally deployed, open-source LLMs could adjudicate heart failure hospitalizations. The result: 96.8% accuracy ahajournals.org/doi/full/10.…
1
9
41
3,410
Importantly: The model’s agreement with cardiologists was similar to the agreement between two board-certified cardiologists. No cloud API. No external data transfer. No patient data leaving the hospital’s servers.
1
2
356
Endpoint adjudication involves significant cost, complexity, and delay. Local AI could help make trials faster, cheaper, and more scalable, while preserving privacy, security, and institutional data governance. Incredible team effort across MIT, Harvard, and Mount Sinai
2
216
Excited to share our new @JACCJournals paper! Among 8.4M US adults with prior MI, we found major secondary prevention gaps : ~1/2 met BP or A1c targets, <1/3 met LDL-C <70, and ~1/6 met LDL-C <55. ⭐team: #PeterLibby @Gong2Jingyi @DLBHATTMD @rkwadhera 🔗lnkd.in/dCtimruV
9
21
1
108
14,183
Rahul Aggarwal retweeted
🧵1/ Our new study on AI and physician reasoning just came out in @ScienceMagazine. As co-senior author, I'm excited about our findings, and I do think AI will reshape medicine. But after seeing some of the discussions, I'm also worried about how our findings may be misinterpreted.
32
160
36
524
165,422
Terrific work by budding stars @nikhilpatelll @ashwin !! Check out our article in AJPC: sciencedirect.com/science/ar… Thankful to @DLBHATTMD and @RahulAggarwalMD for their guidance and @khurramn1 for the opportunity
2
9
1,418